COVID-19 in a patient with systemic sclerosis with pulmonary fibrosis: case report
DOI:
https://doi.org/10.11606/issn.1679-9836.v100i6p599-604Keywords:
Scleroderma, Systemic, Pulmonary Fibrosis, Coronavirus Infections, Immunosuppressive AgentsAbstract
This report aims to describe a case of COVID-19 in a female patient, 48 years old, with diffuse cutaneous Systemic Sclerosis (dcSSc) for 14 months associated with pulmonary fibrosis, using mycophenolate mofetil (MMF). The patient was admitted to the hospital with a one-week history of cough and fever. After 4 days, she tested positive for COVID-19. She was discharged after 11 days. Immunosuppressants are expected to predispose a greater risk of infections and consequent greater aggression to the organism. This report aimed to analyze this correlation, since the patient survived the infection and did not have a severe form of the disease. Although this report describes a patient’s favorable evolution, the relevance of further studies to assess the effects of immunosuppression on COVID-19 is highlighted.
Downloads
References
Singhal T. A Review of coronavirus disease-2019 (COVID-19). Indian J Pediatr. 2020;87(4):281-6. doi: 10.1007/s12098-020-03263-6.
Del Papa N, Sambataro G, Minniti A, Pignataro F, Caporali R. Novel COrona virus disease 2019 (COVID-19) epidemic: what are the risks for systemic sclerosis patients. Autoimmun Rev. 2020;19:102558. doi: 10.1016/j.autrev.2020.102558.
Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ. 2020;368:m1198. doi: 10.1136/bmj.m1198.
Emmi G, Bettiol A, Mattioli I, Silvestri E, Di Scala G, Urban ML, et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev. 2020;19(7):102575. doi: 10.1016/j.autrev.2020.102575.
Shin YH, Shin JI, Moon SY, Jin HY, Kim SY, Yang JM, et al. Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study. Lancet Rheumatol. 2021;3(10):e698-e706. doi: 10.1016/S2665-9913(21)00151-X.
Shenoy P, Ahmed S, Shanoj KC, Shenoy V, Damodaran D, Menon AR, et al. Antibody responses after documented COVID-19 disease in patients with autoimmune rheumatic disease. Clin Rheumatol. 2021; 40(11):4665-70. doi: 10.1007/s10067-021-05801-9.
van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-55. doi: 10.1136/annrheumdis-2013-204424.
Sampaio-Barros PD, Zimmermann AF, Müller CS, Borges CTL, Freire EAM, Martí GB, et al. Recomendações sobre diagnóstico e tratamento da esclerose sistêmica. Rev Bras Reumatol. 2013;53(3):258-75. doi: http://dx.doi.org/10.1590/S0482-50042013000300004.
Fernández-Codina A, Walker KM, Pope JE; Scleroderma Algorithm Group. Treatment Algorithms for Systemic Sclerosis According to Experts. Arthritis Rheumatol. 2018;70(11):1820-8. doi: 10.1002/art.40560.
Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913. doi: 10.1183/13993003.01913-2018.
Akyıl FT, Karadoğan D, Gürkan CG, Yüksel A, Arıkan H, Eyüboğlu TŞ, et al. What we learned about COVID-19 so far? Notes from underground. Turk Thorac J. 2020;21(3):185-92. doi: 10.5152/TurkThoracJ.2020.20052.
Yun JSW, Yap T, Martyres R, Kern JS, Varigos G, Scardamaglia L. The association of mycophenolate mofetil and human herpes virus infection. J Dermatolog Treat. 2020;31(1):46-55. doi: 10.1080/09546634.2019.1572864.
Russell B, Moss C, George G, Santaolalla A, Cope A, Papa S, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020; 27;14:1022. doi: 10.3332/ecancer.2020.1022.
Salim PH, Xavier RM. Influence of genetic polymorphisms (IL-10/CXCL8/CXCR2/ NFκB) on the susceptibility of autoimmune rheumatic diseases. Rev Bras Reumatol. 2014;54(4):301-10. doi: 10.1016/j.rbr.2013.10.006.
Gourh P, Arnett FC, Assassi S, Tan FK, Huang M, Diekman L, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther. 2009;11(5):R147. doi: 10.1186/ar2821.
Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568. doi: 10.1016/j.autrev.2020.102568.
Orlandi M, Lepri G, Bruni C, Wang Y, Bartoloni A, Zammarchi L, et al. The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress. Clin Rheumatol. 2020;39(7):2043-7. doi: 10.1007/s10067-020-05193-2.
Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963-74. doi: 10.1016/S2213-2600(20)30318-0. Erratum in: Lancet Respir Med. 2020;8(10):e75. Erratum in: Lancet Respir Med. 2021;9(3):e29.
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect. 2020;80(6):607-13. doi: 10.1016/j.jinf.2020.03.037.
Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16-32. doi: 10.1128/MMBR.05015-11.
von Borstel A, Abdulahad WH, Dekkema G, Rutgers A, Stegeman CA, Veldman J, et al. Mycophenolic acid and 6-mercaptopurine both inhibit B-cell proliferation in granulomatosis with polyangiitis patients, whereas only mycophenolic acid inhibits B-cell IL-6 production. PLoS One. 2020;15(7):e0235743. doi: 10.1371/journal.pone.0235743.
Zen M, Fuzzi E, Astorri D, Saccon F, Padoan R, Ienna L, et al. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients. J Autoimmun. 2020;112:102502. doi: 10.1016/j.jaut.2020.102502.
Mihai C, Dobrota R, Schröder M, Garaiman A, Jordan S, Becker MO, et al. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Ann Rheum Dis. 2020;79(5):668-9. doi: 10.1136/annrheumdis-2020-217442.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Ana Clara Naves Vieira, Isabela Souza Cruvinel Borges, Juliana Markus
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
